Valuation: Medivir AB

Market Cap 1.17B 124M 106M 99.37M 90.97M 171M 11.86B 173M 458M 5.96B 466M 455M 19.71B P/E 2026 *
-12.5x
P/E 2027 * -8.7x
Enterprise Value 1.08B 114M 97.52M 91.25M 83.53M 157M 10.89B 159M 420M 5.47B 427M 418M 18.1B EV / Sales 2026 *
180x
EV / Sales 2027 * 7.13x
Free-Float
73.28%
Yield 2026 *
-
Yield 2027 * -
1 day+2.15%
1 week+14.46%
Current month+4.40%
1 month+7.34%
3 months+0.53%
6 months+36.10%
Current year+364.55%
1 week 1.64
Extreme 1.636
2.15
1 month 1.64
Extreme 1.636
2.15
Current year 0.39
Extreme 0.392
2.88
1 year 0.34
Extreme 0.34
2.88
3 years 0.34
Extreme 0.34
8.25
5 years 0.34
Extreme 0.34
11.84
10 years 0.34
Extreme 0.34
102
Manager TitleAgeSince
Chief Executive Officer 55 2022-01-23
Director of Finance/CFO - 2026-03-22
Chief Tech/Sci/R&D Officer 60 2023-02-19
Director TitleAgeSince
Chairman 76 2021-05-04
Director/Board Member 70 2018-05-02
Director/Board Member 47 2021-05-04
Date Insider Type Main position Quantity % Market Cap.
7/27/26
Hallberg Management AB
BuyCompany 6,097,560 0.9868%
6/18/26 Buy

Chief Financial Officer

18,000 0.0033%
12/5/25 Buy 90,000 0.0802%
Change 5-day change 1-year change 3-year change Capi.($)
+2.15%+14.46%-5.00%-73.97% 124M
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
Average +1.34%+8.97%+52.68%+170.51% 28.96B
Weighted average by Cap. +0.74%+9.48%+58.00%+157.76%

Financials

2026 *2027 *
Net sales 5.98M 631K 541K 506K 463K 869K 60.41M 881K 2.33M 30.35M 2.37M 2.32M 100M 144M 15.25M 13.07M 12.22M 11.19M 21M 1.46B 21.28M 56.32M 733M 57.27M 56.03M 2.42B
Net income -77.84M -8.22M -7.04M -6.59M -6.03M -11.32M -787M -11.47M -30.36M -395M -30.87M -30.2M -1.31B 33.13M 3.5M 3M 2.8M 2.57M 4.82M 335M 4.88M 12.92M 168M 13.14M 12.85M 556M
Net Debt -96M -10.14M -8.68M -8.13M -7.44M -13.96M -970M -14.14M -37.44M -487M -38.07M -37.24M -1.61B -145M -15.31M -13.12M -12.27M -11.23M -21.08M -1.47B -21.36M -56.55M -736M -57.5M -56.25M -2.43B
Logo Medivir AB
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Employees
7
Date Price Change Volume
26-08-21 SEK 1.900 +2.15% 6,388,283
26-08-20 SEK 1.860 +10.06% 3,447,980
26-08-19 SEK 1.690 +2.05% 924,356
26-08-18 SEK 1.656 -2.82% 1,367,720
26-08-17 SEK 1.704 +2.65% 589,462
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.900SEK
Average target price
5.468SEK
Spread / Average Target
+187.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MVIR B Stock